I guess I didn't look at it that way, but would they still continue development of that drug even though there are other polymerase inhibitors out there with greater effects? I think one thing that is tough to factor in when doing assumptions, is that right now I think most assume 48 week tx for possible revenue from any drug, when in fact, it might not be by the time it is approved. Very hard to calculate value for any other partnered compound IMO.
Ribavirin is also a polymerase inhibitor, right? So, any developer of similar drugs has to compare them against Rib wrt efficacy and side effect. If the comparison is not favorable against Rib, the drug should not be developed.